The Future of Cardiac Resynchronization Therapy Patient Selection?
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
See Article by Kalscheur et al
Cardiac resynchronization therapy (CRT) is a well-proven therapy for a select group of patients with symptomatic heart failure (HF) with a reduced ejection fraction and interventricular conduction delay. Multiple large, prospective, randomized trials have established the potential for CRT to improve quality of life, exercise capacity, and systolic function, as well as reduce heart failure hospitalizations and mortality.1–5 Despite the large and consistent overall benefit of CRT noted in clinical trials, a significant proportion of patients are considered nonresponders or partial responders on the basis of a variety of objective and subjective measures.1–6
Several factors have been identified, which are associated with CRT response rate, including patient selection, device programming, and lead position. With regard to patient selection, the US and European guidelines …